Clinical Trials
28 trialsTT4B
University of Arkansas
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Hoosier Cancer Research Network
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Roswell Park Cancer Institute
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Shengjing Hospital
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
PDD vs PAD to Treat Initially Diagnosed MM
The First Affiliated Hospital of Soochow University
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma
University of Wisconsin, Madison
ACVDL
Vejle Hospital
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
RAD
University of Athens
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Effects of Exercise in Combination With Epoetin Alfa
University of Arkansas
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Bortezomib-Dexamethasone-Doxorubicin-Study
Austrian Forum Against Cancer
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
University of Arkansas
MAG 2002
University Hospital, Caen
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party